The impact of peritoneal dialysis upon quality of life and mortality of patients with end-stage congestive heart failure

Contributions to Nephrology

Volumn 150, Issue , 2006, Pages 247-253

  Gotloib, Lazaro ^a   Fudin, Roberto ^a  

^a HAEMEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; CONGESTIVE HEART FAILURE; HUMAN; MIDDLE AGED; MORTALITY; PERITONEAL DIALYSIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW;

AGED; HEART FAILURE, CONGESTIVE; HUMANS; MIDDLE AGED; PERITONEAL DIALYSIS; QUALITY OF LIFE;

EID: 33745278223     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000093602     Document Type: Review

References (21)

1. Hunt SA, Baker DN, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Woble RJ, Parker M, Silver MA, Stevenson LW: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2001;104:2996-3007.
2. Jessup M, Brozena S: Heart failure. N Engl J Med 2003;348:2007-2018.
3. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
4. Klein L, O'Connor CM, Gattis WA, Zampino M, de Luca L, Vitarelli A, Fedele F, Gheorghiade M: Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am J Cardio 2003;91:18F-40F.
5. Pitt B, Zaunad F, Remme WJ, Cody R, Cataigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure: randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
6. Juurlink DN, Mandani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier AA: Rates of hyperkalemia after publication of the randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-551.
7. Canaud B, Leblanc M, Leray-Moragnes H, Delmas S, Klouche K, Beraud JJ: Slow continuous and daily ultrafiltration for refractory congestive heart failure. Nephrol Dial Transplant 1998;13(suppl 4): S51-S55.
8. Iorio L, De Santo LS, Violi F: Hemodialytic treatment of cardiac failure. Semin Nephrol 2001;21: 278-281.
9. Schneierson SJ: Continuous peritoneal irrigation in the treatment of intractable edema of cardiac origin. Am J Med Sci 1949;218:76-79.
10. Gotloib L, Fudin R, Yakubovich M, Vienken J: Peritoneal dialysis in refractory end-stage congestive heart failure: a challenge facing a no-win situation. Nephrol Dial Transplant 2005;20(suppl 7):32-36.
11. Tormey V, Conlon PJ, Farrell J, Horgan J, Walshe JJ: Long-term successful management of refractory congestive heart failure by intermittent ambulatory peritoneal ultrafiltration. Q J Med 1996;88:681-683.
12. Ryckelink JP, Lobbedez T, Valette B, Le Goge C, Mazouz O, Levaltier B, Potier JC, Hurault de Ligny B: Peritoneal ultrafiltration and treatment-resistant heart failure. Nephrol Dial Transplant 1998;13(suppl 4):56-59.
13. Costanzo MR, Augustine S, Bourge R, Bristow M, O'Connell JB, Driscoll D, Rose E: Selection and treatment of candidates for heart transplantation. Circulation 1995;92:3593-3612.
14. Boudoulas H, Geleris P, Bush CA, Lewis RP, Fulkerson PK: Assessment of ventricular function by combined non-invasive measures: factors accounting for methodological disparities. Int J Cardiol 1983;2:493-506.
15. Diwan A, Tran T, Misra A, Mann DL: Inflammatory mediators and the failing heart: a translational approach. Curr Mol Med 2003;3:161-182.
16. Zoccali C, Mallamaci F, Benedette FA, Triperi G, Parlongo S, Cataliotti S, Cutrupi A, Giacone G, Bellanuova I, Cottini E, Malatino LS: Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001;12:1508-1515.
17. Horl WH, Riegel W: Cardiac depressant factors in renal disease. Circulation 1993;87(suppl 5): IV77-IV82.
18. Babb AL, Johansen PJ, Strand MJ, Tenckhoff H, Scribner BH: Bi-directional permeability of the human peritoneum to middle molecules. Proc Eur Dial Transplant Assoc 1973;10:247-262.
19. Zemel D, Imholz AL, de Waart DR, Dinkla C, Strujik DG, Krediet RT: Appearance of tumor necrosis factor-alpha and soluble TNF receptors I and II in peritoneal effluent. Kidney Int 1994;46:1422-1430.
20. Fincker ME, Campbell HT, Sklar AH, Carvana RJ, Lightfoot BD, Cheek PL, Smith KL, Hess CP: Atrial natiuretic peptide (ANP) is removed by peritoneal dialysis in humans. Adv Perit Dial 1989; 5:16-19.
21. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT: Anti-TNF therapy against congestive heart failure. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-3140.